Buchumschlag

Dietary factors and patterns in relation to risk of later‐onset ulcerative colitis in Chinese: A prospective study of 0.5 million people

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Shuyao Song, Zhiyu Wu, Jun Lv, Canqing Yu, Dianjianyi Sun, Pei Pei, Lang Pan, Ling Yang, Yiping Chen, Huaidong Du, Lingli Chen, Dan Schmidt, Daniel Avery, Liping Duan, Junshi Chen, Zhengming Chen, Liming Li, Yuanjie Pang
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2024
Schlagworte:	Alimentary Pharmacology & Therapeutics
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Letter: Should ulcerative colitis be monitored more or less invasively?
von: David Laharie
Veröffentlicht: (2024)

Letter: Should ulcerative colitis be monitored more or less invasively? Authors' reply
von: Matthias Lenfant, et al.
Veröffentlicht: (2024)

Recent steroid use and the relapse risk in ulcerative colitis patients with endoscopic healing
von: Tomohiro Fukuda, et al.
Veröffentlicht: (2024)

Long‐term benefit of ustekinumab in ulcerative colitis in clinical practice: ULISES study
von: María Chaparro, et al.
Veröffentlicht: (2024)

Editorial: Sequencing rescue therapy for acute severe ulcerative colitis—Ready for revision?
von: L. A. A. P. Derikx, et al.
Veröffentlicht: (2024)

Editorial: Mucosal healing with steroids: Once upon a time in ulcerative colitis
von: Manuel Barreiro‐de Acosta, et al.
Veröffentlicht: (2024)

Predicting complications in paediatric ulcerative colitis: A longitudinal multicentre cohort study
von: Merle Claßen, et al.
Veröffentlicht: (2024)

A personalised algorithm predicting the risk of intravenous corticosteroid failure in acute ulcerative colitis
von: Anthony Croft, et al.
Veröffentlicht: (2024)

Editorial: Effectiveness and safety of ustekinumab in ulcerative colitis—Where we are now in real life
von: Giammarco Mocci, et al.
Veröffentlicht: (2024)

Efficacy and safety of filgotinib for ulcerative colitis: A real‐world multicenter retrospective study in Japan
von: Shintaro Akiyama, et al.
Veröffentlicht: (2024)

Editorial: Mucosal healing with steroids—Once upon a time in ulcerative colitis. Authors' reply
von: Tomohiro Fukuda, et al.
Veröffentlicht: (2024)

Editorial: Extending upadacitinib induction dosing in ulcerative colitis‐A delicate balance of efficacy and safety
von: Shintaro Sagami, et al.
Veröffentlicht: (2024)

Editorial: Sequencing rescue therapy for acute severe ulcerative colitis—Ready for revision? Authors' reply
von: María José García, et al.
Veröffentlicht: (2024)

Adiposity and risks of gastrointestinal cancers: A 10‐year prospective study of 0.5 million Chinese adults
von: Wing Ching Chan, et al.
Veröffentlicht: (2024)

Editorial: Extending upadacitinib induction dosing in ulcerative colitis—A delicate balance of efficacy and safety. Author's reply
von: Remo Panaccione
Veröffentlicht: (2024)

Letter: Third‐line therapy in acute severe ulcerative colitis, exploring the uncertainty and unanswered questions—Authors' reply
von: María José García, et al.
Veröffentlicht: (2024)

Letter: Critical appraisal of biologic therapy in early ulcerative colitis management—Addressing study limitations and the role of psychological resilience—Authors' reply
von: Vibeke Strande, et al.
Veröffentlicht: (2024)

Higher end‐of‐treatment HBsAg levels is associated with later onset but not severe relapse in HBeAg‐negative chronic hepatitis B patients stopping antivirals
von: Yen‐Chun Liu, et al.
Veröffentlicht: (2024)

Letter on ‘Non‐Response to Obeticholic Acid Is Associated With Heightened Risks of Developing Clinical Events in Primary Biliary Cholangitis’
von: Yi Pei, et al.
Veröffentlicht: (2025)

Letter: Potential confounders might exaggerate the risk of rheumatoid arthritis in patients with microscopic colitis
von: Fang Yan, et al.
Veröffentlicht: (2024)

Letter: Advancing Serologic Classification in Indeterminate Chronic Hepatitis B Through Dynamic and Integrated Frameworks
von: Chun‐Chieh Chen, et al.
Veröffentlicht: (2025)

Letter: Potential confounders might exaggerate the risk of rheumatoid arthritis in patients with microscopic colitis—Authors' reply
von: David Bergman, et al.
Veröffentlicht: (2024)

Editorial: Beyond Viral Eradication—Cardiometabolic Risk and Cardiovascular Outcomes After SVR in Chronic Hepatitis C. Authors' Reply
von: Pei‐Chien Tsai, et al.
Veröffentlicht: (2026)

Editorial: Accelerometers to Quantify Physical Activity in MASLD—Impact on Clinical Outcomes
von: Vincent L. Chen
Veröffentlicht: (2025)

Editorial: Inflammatory Bowel Disease and Dietary Emulsifiers—A Conundrum That Continues
von: Stephanie Gold, et al.
Veröffentlicht: (2025)

Letter: Dietary emulsifiers and intestinal health—The beginning of an evolving story: Authors’ reply
von: Jessica A. Fitzpatrick, et al.
Veröffentlicht: (2024)

Editorial: Inflammatory Bowel Disease and Dietary Emulsifiers—A Conundrum That Continues. Authors' Reply
von: Jessica A. Fitzpatrick, et al.
Veröffentlicht: (2025)

Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral‐Induced Cure of Hepatitis C Virus Infection
von: Yu‐Ping Chang, et al.
Veröffentlicht: (2025)

Paediatric‐onset immune‐mediated inflammatory disease is associated with an increased mortality risk—A nationwide study
von: Mikkel Malham, et al.
Veröffentlicht: (2024)

Letter: Unlocking the Full Potential of Dietary Therapy in IBD —The Case for Universal Eating Disorder Screening
von: Luisa Bertin, et al.
Veröffentlicht: (2026)

Editorial: Food for Thought—Addressing the Nuances of Diet and Mood When Evaluating Dietary Intervention in IBS
von: Cecilia Katzenstein, et al.
Veröffentlicht: (2024)

Letter: Extreme diagnostic delay due to misdiagnosis of gastrointestinal tuberculosis later diagnosed as postoperative Crohn's disease
von: Abhirup Chatterjee, et al.
Veröffentlicht: (2024)

Letter: Late Diagnosis of Chronic Hepatitis B—Quantifying the Missed Opportunities and Clinical Consequences
von: Bi‐Yu Gao, et al.
Veröffentlicht: (2025)

Letter: Refining the Understanding of Hepatic Steatosis and Cardiovascular Risk—Addressing Key Variables and Subgroup Analyses
von: Changhu Sun, et al.
Veröffentlicht: (2025)

Letter: Differences in Disease Characteristics and Treatment Exposures Between Paediatric and Adult‐Onset IBD
von: Xinli Chen, et al.
Veröffentlicht: (2024)

Letter: The Unresolved Issue of NSBB Confounding in Statin Research for Cirrhosis
von: Deliang Huang, et al.
Veröffentlicht: (2026)

Editorial: High Baseline ALT Level Confers Risk of Hepatic Adverse Events During Immune Checkpoint Inhibitors Treatment: A Call for Caution
von: Ze‐Hua Zhao, et al.
Veröffentlicht: (2025)

Hepatic Events During Immune Checkpoint Inhibitor Treatment Between Liver and Non‐Liver Malignancies in Hepatitis B Endemic Areas
von: Yi‐Ping Hung, et al.
Veröffentlicht: (2024)

Impact of HCV eradication on recurrence pattern and long‐term outcomes in patients with HCV‐related hepatocellular carcinoma undergoing radiofrequency ablation
von: Kuo‐Cheng Wu, et al.
Veröffentlicht: (2024)

Editorial: Food for Thought—Addressing the Nuances of Diet and Mood When Evaluating Dietary Intervention in IBS. Authors' Reply
von: Anthony O'Connor, et al.
Veröffentlicht: (2024)